Physician profile
Michael C Chase
NPI 1457423105
$1,346.03
in general payments reported to CMS, 2019-2025
19 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,102 · 2020: $195 · 2021: $48.73.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $264.95 | 2019-2021 | |
| Pfizer INC. | $208.31 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $184.87 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $171.67 | 2019-2020 | |
| Edwards Lifesciences Corporation | $144.69 | 2019-2020 | |
| Lilly USA, LLC | $62.90 | 2019-2021 | |
| Astrazeneca Pharmaceuticals Lp | $59.67 | 2019 | |
| Astellas Pharma US INC | $37.05 | 2019-2020 | |
| Boston Scientific Corporation | $34.60 | 2019 | |
| Abbvie INC. | $24.17 | 2019 | |
| Shire North American Group INC | $22.28 | 2019 | |
| Janssen Scientific Affairs, LLC | $20.62 | 2019 | |
| Merck Sharp & Dohme LLC | $18.69 | 2020 | |
| Circassia INC. | $17.59 | 2019 | |
| Celgene Corporation | $16.98 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $16.66 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $15.79 | 2021 | |
| Novo Nordisk INC | $12.56 | 2019 | |
| Allergan, INC. | $11.98 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Chase listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.